PURPOSE: This study was undertaken to determine the antibiotic susceptibility and minimum inhibitory concentrations (MIC) of amikacin, tobramycin, ciprofloxacin, gatifloxacin, azithromycin, and clarithromycin against rapidly growing nontuberculous mycobacteria isolated from patients with keratitis. METHODS: A total of 15 rapidly growing nontuberculous mycobacteria isolated from corneal scrapings of keratitis patients from January 1999 through December 2007 were subjected to antimicrobial susceptibility testing by the E-Test to amikacin, tobramycin, ciprofloxacin, gatifloxacin, azithromycin, and clarithromycin. RESULTS: Out of 15 isolates, 13 were identified as Mycobacterium chelonae complex and 2 as Mycobacterium fortuitum complex. Based on minimum inhibitory concentration (MIC) cut off, all 15 (100%) isolates were sensitive to amikacin, azithromycin, and clarithromycin, 13 (86%) were sensitive to tobramycin, nine (60%) to gatifloxacin, and only 6 (40%) to ciprofloxacin. The MIC range was 0.25-4 microg/ml for amikacin, 0.5-1 microg/ml for azithromycin, 0.125-1 microg/ml for clarithromycin, 0.5-16 microg/ml for ciprofloxacin, and 0.25-16 microg/ml for tobramycin. MIC(90) for amikacin was 2 microg/ml, azithromycin 1 microg/ml, clarithromycin 0.75 microg/ml, ciprofloxacin 8 microg/ml, gatifloxacin 8 microg/ml, and for tobramycin it was 4 microg/ml. CONCLUSIONS: All the isolates were sensitive to amikacin, azithromycin, and clarithromycin, but the MIC values of clarithromycin and azithromycin were lower than amikacin. Based on in vitro susceptibility results it appears that the topical amikacin in combination with oral clarithromycin or azithromycin is the best treatment option for rapidly growing nontuberculous mycobacterial keratitis.
PURPOSE: This study was undertaken to determine the antibiotic susceptibility and minimum inhibitory concentrations (MIC) of amikacin, tobramycin, ciprofloxacin, gatifloxacin, azithromycin, and clarithromycin against rapidly growing nontuberculous mycobacteria isolated from patients with keratitis. METHODS: A total of 15 rapidly growing nontuberculous mycobacteria isolated from corneal scrapings of keratitispatients from January 1999 through December 2007 were subjected to antimicrobial susceptibility testing by the E-Test to amikacin, tobramycin, ciprofloxacin, gatifloxacin, azithromycin, and clarithromycin. RESULTS: Out of 15 isolates, 13 were identified as Mycobacterium chelonae complex and 2 as Mycobacterium fortuitum complex. Based on minimum inhibitory concentration (MIC) cut off, all 15 (100%) isolates were sensitive to amikacin, azithromycin, and clarithromycin, 13 (86%) were sensitive to tobramycin, nine (60%) to gatifloxacin, and only 6 (40%) to ciprofloxacin. The MIC range was 0.25-4 microg/ml for amikacin, 0.5-1 microg/ml for azithromycin, 0.125-1 microg/ml for clarithromycin, 0.5-16 microg/ml for ciprofloxacin, and 0.25-16 microg/ml for tobramycin. MIC(90) for amikacin was 2 microg/ml, azithromycin 1 microg/ml, clarithromycin 0.75 microg/ml, ciprofloxacin 8 microg/ml, gatifloxacin 8 microg/ml, and for tobramycin it was 4 microg/ml. CONCLUSIONS: All the isolates were sensitive to amikacin, azithromycin, and clarithromycin, but the MIC values of clarithromycin and azithromycin were lower than amikacin. Based on in vitro susceptibility results it appears that the topical amikacin in combination with oral clarithromycin or azithromycin is the best treatment option for rapidly growing nontuberculous mycobacterial keratitis.
Authors: I B Ramis; M Cnockaert; A von Groll; C L Nogueira; S C Leão; E Andre; A Simon; J C Palomino; P E A da Silva; P Vandamme; A Martin Journal: Eur J Clin Microbiol Infect Dis Date: 2015-03-29 Impact factor: 3.267
Authors: Katrina E V Jones; Michala de Linde Henriksen; Søren Saxmose Nielsen; Joshua B Daniels; Michael R Lappin Journal: Vet Ophthalmol Date: 2022-02-28 Impact factor: 1.444